Milestone Pharmaceuticals's operating income is $-79M.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
Milestone Pharmaceuticals (MIST) currently reports a operating income of $-79M as of June 2026. That compares with $-55M in the prior-year period — down 42.8% year over year. Use the charts on this page to explore Milestone Pharmaceuticals's operating income history and peer comparisons.
Milestone Pharmaceuticals's operating income decreased from $-55M to $-79M — a 42.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Milestone Pharmaceuticals reported $-79M in operating income as of June 2026. That compares with $-55M in the prior-year period — down 42.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $-79M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Milestone Pharmaceuticals, and consider following MIST for alerts when major investors trade the stock.
Milestone Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-79M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MIST with unrelated industries.